Ralph A. DeFronzo

Sep 4, 2024 | hcplive.com | Natalie Bellini |Ralph A. DeFronzo |Athena Philis-Tsimikas |John Anderson

September 4, 2024By Panelists discuss how treating hypercortisolism in patients may have long-term effects on glycemic control and overall health, potentially influencing future standards of care for difficult-to-control Type 2 diabetes, while emphasizing the need for clinicians to carefully manage such patients as ongoing research continues.

Aug 28, 2024 | hcplive.com | Natalie Bellini |Ralph A. DeFronzo |Athena Philis-Tsimikas |John Anderson

August 28, 2024By Experts discuss the CATALYST study's evaluation of mifepristone for hypercortisolism patients with hard-to-manage type 2 diabetes, its mechanism of action, suitable patient populations, treatment approaches for those with adrenal tumors, and factors determining surgical candidacy.

Aug 21, 2024 | hcplive.com | Natalie Bellini |Ralph A. DeFronzo |Athena Philis-Tsimikas |John Anderson

August 21, 2024By Medical experts explore why findings from this study are crucial for clinicians managing diabetes, particularly those in primary care settings, and how these insights can impact their approach to patient care. Video content above is prompted by the following:Why should clinicians who manage patients with diabetes, the majority of whom are in the primary care setting, care about the findings from this study? Related Content Related Content

Aug 21, 2024 | hcplive.com | Natalie Bellini |Ralph A. DeFronzo |Athena Philis-Tsimikas |John Anderson

August 21, 2024By Medical experts discuss the implications of finding hypercortisolism in one-third of patients on three or more hypertension medications, the linkage between hypercortisolism and type 2 diabetes as presented in the ‘Pathologic Mechanisms of Hypercortisolism in Type 2 Diabetes’ session, and how hypercortisolism affects diabetes management, including the importance of addressing it and its consequences for patients with difficult-to-control diabetes.

Aug 14, 2024 | hcplive.com | Natalie Bellini |Ralph A. DeFronzo |Athena Philis-Tsimikas |John Anderson

August 14, 2024By The panel of medical experts discuss the prevalence of hypercortisolism based on the CATALYST trial. Video content above is prompted by the following:What were the key findings from Part 1: Prevalence phase of the CATALYST study? How does the data from the CATALYST trial change the narrative about the true prevalence of hypercortisolism in diabetes? How does this prevalence data fit with the growing body of evidence regarding autonomous adrenal cortisol secretion?